Genmab — Februar 2024

[gdn55]

Er dette ikke en dansk chat?

[Bulder]

Sc hex 38 er i hvert fald et nyt statement. Winkel er blevet spurgt flere gange, og sagt, at det var for tidligt at afgøre.

[KWC]

Konkurence ? https://www.biospace.com/article/gsk-s-blenrep-scores-phase-iii-win-in-multiple-myeloma/?utm_campaign=Daily Social | News&utm_content=281354534&utm_medium=social&utm_source=facebook&hss_channel=fbp-10530620221

[KWC]

GSK’s Blenrep Combo Scores Phase III Win in Multiple Myeloma

[Bulder]

En vis konkurrence - i 2. linje. 1/3 får grad 3 eller værre problemer med synet.

[Helge_LarsenPI-redaktør]

Godmorgen

[Plimsoller]

God morgen

[Stroka]

God morgen

[LP90]

God morgen

[E_L]

AMGEN: TEPEZZA (teprotumumab-trbw) generated $448 million of sales for the period. TEPEZZA is the first and only FDA-approved treatment for thyroid eye disease (TED). -Sales figures reflect only sales in the period from Oct. 6 2023 through the end of the year, and not the full quarter. https://investors.amgen.com/news-releases/news-release-details/amgen-reports-fourth-quarter-and-full-year-2023-financial

[E_L]

In December 2023, TEPEZZA received orphan drug designation in Japan for patients with moderate to severe active thyroid eye disease (TED).
A New Drug Application was submitted for TEPEZZA in Japan based on the results from the OPTIC-J study evaluating TEPEZZA in patients with active TED.
A Phase 3 study of TEPEZZA in Japan for chronic or low clinical activity score (CAS) TED continues to enroll patients.

[E_L]

The Company plans to initiate a Phase 3 study evaluating the subcutaneous route of administration of TEPEZZA in patients with TED in H1 2024.

[Sukkeralf]

UUHFFF - now we hate these sc versions

[Sukkeralf]

But Amgen seems to being doing a good job - thats so good

[Sukkeralf]

Lundbeck igangsætter
fase 3-studie med Lu AF82422.

[Sukkeralf]

Lundbeck igangsætter fase 3-studie med CNS-kandidat

På trods af de umiddelbart ufordelagtige statistiske resultater fra et tidligere studie igangsætter Lundbeck nu et fase 3-studie med Lu AF82422.

(medwatch.dk)

[E_L]

we'll see how that works out for Tepezza SC, we don't know if the contracts are similar, but at at least Genmab now knows how to proceed with a potential arbitrage The news in itself is not real news in that Horizon was looking at SC already in 2020 with Halozyme, but i imagine Xeris Biopharma will run with the deal after this
https://finance.yahoo.com/news/xeris-xers-licensing-deal-amgen-133000124.html

[gentogen]

Når nu SC-versionerne juridisk set er helt nye produkter, kan Genmab så ikke bare selv lave dem?

[E_L]

the Ph3 EPCORE FL-2 trials started recruiting https://classic.clinicaltrials.gov/ct2/history/NCT06191744?B=3&A=2&C=merged#StudyPageTop

[JørgenVarnæs]

Nice - full steam ahead. Any ideas as to how easy/difficult recruitment will be?